Linvoseltamab is an investigational BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with CD3-expressing T cells to facilitate T-cell activation and ...
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
A novel AI model was able to achieve 99.86% accuracy for diagnosing skin conditions, even in people with darker skin tones or ...
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback